posted
ULGX: FDA Approves Cooled ThermoCath 4.5+ Treatment Catheter
Urologix(R), Inc. (ULGX) has received approval from the FDA for its Cooled ThermoCath(R) 4.5+, a single-use treatment catheter designed to treat benign prostatic hyperplasia (BPH) effectively in patients with larger prostates. The catheter is used with Urologix' Targis(R) system to deliver Cooled ThermoTherapy(TM), targeted microwave energy combined with a unique cooling mechanism to enhance patient comfort. The company will begin marketing the new catheter this month.
Urologix has also gained recent FDA approvals for expanding the patients eligible for Cooled ThermoTherapy treatment. Some BPH patients are unable to void and therefore rely on a catheter to empty their bladder, a condition known as retention. These retention patients are now able to be treated with Urologix Cooled ThermoTherapy. Until this recent FDA approval, these patients have had only one option - a surgical procedure. Urologix also gained FDA approval to remove the contraindication of treating patients who wear Defibrillators or Pacemakers (2.6 inches or greater from the urethra). In addition, patients with a prostatic condition referred to as "Median Lobe" are now able to be treated with Cooled ThermoTherapy with a precaution for only those patients with a specific "Ball Valve" type of Median Lobe
posted
July 13, 2005 10:22 AM ETUrologix Gets FDA OK for ThermoCathadvertisementRelated information E-mail this article Print-friendly versionStocks mentioned in this articleUrologix, Inc.(ULGX) Quote, Chart, News Related topicsMovers
All Associated Press NewsMINNEAPOLIS (AP) - Medical device maker Urologix Inc. said Wednesday that the Food and Drug Administration granted marketing approval for one of its catheters designed to treat an enlarged prostate.
The company's shares soared $2.32, or 51.2 percent, to $6.85 in morning trading on the Nasdaq following the news, and rose as high as $7.39 earlier in the day. The stock has traded in a range of $3.76 to $13.88 over the past 52 weeks.
posted
Urologix shares jump on FDA catheter approval
July 13, 2005 12:04:04 (ET)
NEW YORK, July 13 (Reuters) - Urologix Inc.(ULGX,Trade) said on Wednesday it received U.S. Food and Drug Administration approval for a longer-length, single-use treatment catheter for enlarged prostates.
The agency also expanded labeling for the company's Cooled ThermoTherapy treatment for patients implanted with defibrillators or pacemakers.
Shares of Minneapolis, Minnesota-based Urologix jumped on the news, rising $1.62, or 35.76 percent, to $6.15 Wednesday on Nasdaq.
The treatment, called Cooled ThermoTherapy, uses microwave energy and a cooling mechanism to treat benign prostatic hyperplasia, a condition that can make urination difficult or painful.
posted
Looks like I found this about 4 months before the pay service did. Looks like a good buy in time now IMO. Should be a good hold for the coming year if anyone is looking to park some cash.
quote:Originally posted by Peaser01: Looks like I found this about 4 months before the pay service did. Looks like a good buy in time now IMO. Should be a good hold for the coming year if anyone is looking to park some cash.
------------------------------------------------- Looks like the paid service knows what it is doing..
And are you trying to say the companys pay this service?
posted
Not at all. A highly reputable stock picker, which I can not name do to my contract signature, appears to be watching this. No debt here. Looks good for me to make some more money on it! This was a good buy above $5 IMHO for the long haul. Short-term this looks decent as well IMHO.
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
